ArticleJTO clinical and research reports2024

Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study.

Hirotsugu Kenmotsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.